Treatment of Mild-moderate Clostridium Difficile Infection (CDI)

Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged 18 to 89 * In good general health as evidenced by medical history or Diagnosed with specific condition/disease or Exhibits specific clinical signs or symptoms or physical/oral examination findings * Participant has a diagnosis of CDI defined as (i) presence of diarrhea with 4 or more unformed stools within 24 hours and (ii) positive test for toxigenic C. difficile from stools collected within 7 days. * Participants received \< 24 h of SOC therapy for CDI. * Participants presented with primary CDI episode or any number of CDI relapse recurrence of CDI * Participants comply with the eligibility criteria and willing to participate in the study including the 8 week post treatment follow up period. * White Blood Cell absolute neutrophil count \<15 x 109/L, * Women of reproductive potential must use highly effective contraception. For those with child bearing potential, the following methods of birth control are required from Visit 1 up to at least 30 days after study treatment discontinuation: 1). Diaphragm, female condom or cervical cap, partner's use of a condom, any of which must be used in combination with a spermicide; 2). Intra-uterine device; 3). Oral or injectable contraceptive agen…